Skip to Main Content
Important information:
Important Information Regarding Medicare Advantage Plans – Learn More.
  • Sylvester Comprehensive Cancer Center |
  • Bascom Palmer Eye Institute
University of Miami Health
  • Appointments
  • Pay a Bill
  • Refer a Patient
  • International Patients
  • Donate Now
  • Search
  • Patient Login
  • Find a Doctor
  • Treatments Page 1
    Featured Treatments For
    • Allergy and Immunology
    • Arthritis (Rheumatology)
    • Bariatrics (Weight Loss Surgery)
    • Cancer (Oncology)
    • Cardiac and Vascular
    • Concierge Medicine
    • Dentistry
    • Dermatology
    • Diabetes
    • Ear, Nose, and Throat (ENT)
    • Emergency Care
    • Endocrinology, Diabetes and Metabolism
    • Executive Physicals
    • Eye Care (Ophthalmology)
    • Fertility Center
    • Gastrointestinal
    • Genetics
    • Geriatrics
    • Hepatology
    • High Blood Pressure (Hypertension)
    • Hyperbaric Oxygen Therapy
    • Infectious Diseases
    • Internal Medicine
    • Interventional Radiology
    • Lymphedema
    • Nephrology
    • Neurology
    • Neurosurgery
    • Obstetrics and Gynecology
    • Orthopaedics
    • Pain Management and Palliative Care
    • Pediatrics
    • Physical Medicine and Rehabilitation
    • Plastic Surgery
    • Primary Care
    • Psychiatry
    • Pulmonary Medicine
    • Radiology
    • Sleep Medicine
    • Sports Medicine Institute
    • Surgery
    • Transplant
    • UHealth Comprehensive Women’s Health Alliance
    • UHealth Premier
    • Urology
    View all Treatments
    Browse A-Z A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
    Featured Treatments For
    • Allergy and Immunology
    • Arthritis (Rheumatology)
    • Bariatrics (Weight Loss Surgery)
    • Cancer (Oncology)
    • Cardiac and Vascular
    • Concierge Medicine
    • Dentistry
    • Dermatology
    • Diabetes
    • Ear, Nose, and Throat (ENT)
    • Emergency Care
    • Endocrinology, Diabetes and Metabolism
    • Executive Physicals
    • Eye Care (Ophthalmology)
    • Fertility Center
    • Gastrointestinal
    • Genetics
    • Geriatrics
    • Hepatology
    • High Blood Pressure (Hypertension)
    • Hyperbaric Oxygen Therapy
    • Infectious Diseases
    • Internal Medicine
    • Interventional Radiology
    • Lymphedema
    • Nephrology
    • Neurology
    • Neurosurgery
    • Obstetrics and Gynecology
    • Orthopaedics
    • Pain Management and Palliative Care
    • Pediatrics
    • Physical Medicine and Rehabilitation
    • Plastic Surgery
    • Primary Care
    • Psychiatry
    • Pulmonary Medicine
    • Radiology
    • Sleep Medicine
    • Sports Medicine Institute
    • Surgery
    • Transplant
    • UHealth Comprehensive Women’s Health Alliance
    • UHealth Premier
    • Urology
    View all Treatments
  • Locations
  • Patients & Families
    Quick links
    • Appointments
    • Pay a Bill
    • Make a Gift
    • Insurance Plans Accepted
    • MyUHealthChart
    • Advance Directives
    For Patients & Families
    • Your First Visit
    • Medical Records
    • Frequently Asked Questions
    • Patient and Caregiver Resources
    • Patients & Families
    • Public Transportation
    • UHealth Clinic at Walgreens
    • Classes & Events
    • Support Groups
    • Interpreter Services
    • International Patients
    • UMiami Health Talks
    About Uhealth
    • Why Choose UHealth
    • Benefits of an Academic Medical Center
    • Mission & Values
    • Leadership
    • Community Health Improvement
    • Nursing at UHealth
    • Health News
    • Miller School of Medicine
    • University of Miami
    • Careers
    • Volunteers
    • Contact Us
    Clinical Trials
    • Find a Clinical Trial
    • Understanding Clinical Trials
    • Clinical Trials FAQ's
    Traveling from overseas?
    We can help plan your visit. Learn More
    Quick links
    • Appointments
    • Pay a Bill
    • Make a Gift
    • Insurance Plans Accepted
    • MyUHealthChart
    • Advance Directives
    For Patients & Families
    • Your First Visit
    • Medical Records
    • Frequently Asked Questions
    • Patient and Caregiver Resources
    • Patients & Families
    • Public Transportation
    • UHealth Clinic at Walgreens
    • Classes & Events
    • Support Groups
    • Interpreter Services
    • International Patients
    • UMiami Health Talks
    About Uhealth
    • Why Choose UHealth
    • Benefits of an Academic Medical Center
    • Mission & Values
    • Leadership
    • Community Health Improvement
    • Nursing at UHealth
    • Health News
    • Miller School of Medicine
    • University of Miami
    • Careers
    • Volunteers
    • Contact Us
    Clinical Trials
    • Find a Clinical Trial
    • Understanding Clinical Trials
    • Clinical Trials FAQ's
Patient Login
  • University of Miami Health System
  • Clinical Trials
  • Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)

Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)

Principal Investigator

Raphael Yechieli

Enrollment Status

Not Accepting

Clinical Trial ID

Institutional Protocol # 20200139
National Clinical Trials Identifier NCT03811002

Clinical Trial Summary

This phase II/III trial studies how well chemotherapy and radiation therapy (chemoradiation)
with or without atezolizumab works in treating patients with limited stage small cell lung
cancer. Drugs used in chemotherapy, such as etoposide, cisplatin, and carboplatin, work in
different ways to stop the growth of tumor cells, either by killing the cells, by stopping
them from dividing, or by stopping them from spreading. Radiation therapy uses high energy
x-rays to kill tumor cells and shrink tumors. Immunotherapy with monoclonal antibodies, such
as atezolizumab, may help the body's immune system attack the cancer, and may interfere with
the ability of tumor cells to grow and spread. Giving chemoradiation with or without
atezolizumab may work better in treating patients with limited stage small cell lung cancer.


Phase

Phase 2/Phase 3


Funding Agency/Sponsor

National Cooperative Group


Disease

Thoracic Oncology


Enrollment Eligibility

Inclusion Criteria:
- Pathologically (histologically or cytologically) proven diagnosis of limited stage
small cell lung cancer (Stage Tx, T1-T4, N0-3, M0, American Joint Committee on Cancer
[AJCC] staging, 8th edition [Ed.]), within 60 days prior to registration
- Patients must have received one cycle of platinum/etoposide chemotherapy
pre-registration (prior to study entry). Study registration must be within 21 days
from day 1 of the pre-registration cycle of chemotherapy.
- Patients must have had measurable disease (per Response Evaluation Criteria in Solid
Tumors [RECIST], version 1.1) prior to the required pre-registration cycle of
platinum/etoposide chemotherapy
- Minimal staging requirements include:
- History/physical examination within 30 days prior to registration
- Positron emission tomography (PET)/computed tomography (CT) scan for staging
within 60 days prior to registration
- CT chest and CT abdomen with IV contrast (unless contraindicated based on kidney
function) within 60 days prior to registration; magnetic resonance imaging (MRI)
abdomen with IV contrast allowed in place of CT abdomen
- Note: If contrast allergy exists, premedication per institutional guidelines
should be performed prior to obtaining CT with contrast. The only exception
to this is a documented life-threatening allergy
- MRI scan of the brain with contrast (preferred) or CT scan of the brain with
contrast (allowable if there is a contraindication with MRI with contrast) within
30 days prior to registration
- Age >= 18
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 within 30 days
prior to registration
- Absolute neutrophil count (ANC) >= 1,500/cells/mm^3 (prior to pre-registration cycle)
- Platelet count >= 100,000 cells/mm^3 (prior to pre-registration cycle)
- Hemoglobin >= 9 g/dL (prior to pre-registration cycle)
- Total bilirubin =< 1.5 x upper limit of normal (ULN) (prior to pre-registration cycle)
- Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and
alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.0 x
ULN (prior to pre-registration cycle)
- Adequate renal function within 30 days prior to registration defined as follows:
Creatinine clearance >= 30 mL/min by the Cockcroft-Gault (C-G) equation
- Patients presenting with a pleural effusion will be eligible if thoracentesis is
cytologically negative and non-bloody or if pleural fluid is too small a volume to
effectively sample by thoracentesis and does not show increased metabolic activity on
CT/PET imaging
- Negative serum pregnancy test within 14 days of registration for pre-menopausal women
of childbearing potential
- The patient or a legally authorized representative must provide study-specific
informed consent prior to study entry
- Hepatitis B/C testing prior to enrollment for patients that have not been tested
before. Note: This is required even if the patient has never shown or had symptoms of
hepatitis
- Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral
therapy with undetectable viral load within 6 months are eligible for this trial
Exclusion Criteria:
- Definitive clinical or radiologic evidence of metastatic disease
- Definitive surgical resection of small cell lung cancer
- Prior invasive malignancy (except non-melanomatous skin cancer, localized prostate
cancer, or any early stage cancer treated with curative intent resection) unless
disease free for a minimum of 2 years (carcinoma in situ of the breast, oral cavity,
or cervix are all permissible)
- More than 1 cycle of prior platinum-based chemotherapy for SCLC prior to enrollment;
note that prior chemotherapy for a different cancer is allowable
- Any prior atezolizumab or other immunotherapy agent
- Prior radiotherapy to the lungs or mediastinum that would result in clinically
significant overlap of radiation therapy fields; prior tangent fields for breast
cancer with minimal overlap with target volumes are allowed per approval of study
principal investigators (PIs)
- Patients with cytologically positive pleural or pericardial fluid are not eligible
- An active, known or suspected autoimmune disease. Patients are permitted to enroll if
they have vitiligo, type I diabetes mellitus, residual hypothyroidism due to
autoimmune condition only requiring hormone replacement, psoriasis not requiring
systemic treatment, or conditions not expected to recur in the absence of an external
trigger
- Active or prior documented inflammatory bowel disease (e.g., Crohn's disease,
ulcerative colitis)
- History of allogeneic organ transplant
- History of primary immunodeficiency
- Severe, active co-morbidity defined as follows:
- Known clinically significant liver disease, including active viral, alcoholic, or
other hepatitis, cirrhosis, fatty liver, and inherited liver disease
- Any other diseases, metabolic dysfunction, physical examination finding, or
clinical laboratory finding giving reasonable suspicion of a disease or condition
that contraindicates the use of an investigational drug or that may affect the
interpretation of the results or render the patient at high risk from treatment
complications
- Active tuberculosis
- Active hepatitis B (chronic or acute) or hepatitis C infection. Note that if
hepatitis status is unknown, hepatitis B/C testing is required
- Patients with past or resolved hepatitis B infection (defined as having a
negative hepatitis B surface antigen [HBsAg]) test, a positive anti-HBc
(antibody to hepatitis B core antigen), and a negative viral
deoxyribonucleic acid (DNA) test (only obtained if HBsAg is found positive)
are eligible
- Patients positive for hepatitis C virus (HCV) antibody are eligible only if
polymerase chain reaction (PCR) is negative for HCV ribonucleic acid (RNA).
(The HCV RNA test must be performed for patients who have a positive HCV
antibody test.)
- Known immunosuppressive disease, for example history of bone marrow transplant or
chronic lymphocytic leukemia (CLL)
- Chronic obstructive pulmonary disease (COPD) requiring chronic oral steroid
therapy of > 10 mg prednisone daily or equivalent at the time of registration.
Inhaled corticosteroids are not exclusionary
- Unstable angina and/or congestive heart failure requiring hospitalization within
the last 3 months
- Transmural myocardial infarction within the last 3 months
- Clinically significant interstitial lung disease
- A condition requiring systemic treatment with either corticosteroids (> 10 mg daily
prednisone equivalents) or other immunosuppressive medications within 14 days of study
drug administration. Inhaled or topical steroids and adrenal replacement doses > 10 mg
daily prednisone equivalents are permitted in the absence of active autoimmune disease
- Pregnancy or women of childbearing potential and men who are sexually active and not
willing/able to use medically acceptable forms of contraception for the duration of
study treatment and for 150 days after the last dose of study drug (Arm 2); this
exclusion is necessary because the treatment involved in this study may be
significantly teratogenic.


Contact Information

Phone Number 305-243-2647
Get detailed information on ClinicalTrials.Gov

logo
alt="Twitter Logo">
USNWR Best Hospitals 2026-2027 USNWR Best Regional Hospitals 2026-2027
Quick links
  • Appointments
  • Find a Doctor
  • Pay a Bill
  • Insurance Plans Accepted
  • MyUHealthChart
  • Make a Gift
Patient & Families
  • Frequently Asked Questions
  • Medical Records
  • Interpreter Services
  • Clinical Trials
  • International Patients
  • UHealth Clinic at Walgreens
  • Support Groups
  • Price Transparency
  • Florida Health Finder
Healthcare Professionals
  • Refer a Patient
  • Physician & Executive Recruitment
  • Advanced Practice Providers
  • Immunology & Histocompatibility Laboratory
  • Nursing
  • Sleep Center
  • Sports Medicine Institute
  • Pathology Reference Services
About Uhealth
  • Why Choose UHealth
  • Benefits of an Academic Medical Center
  • Mission & Values
  • Leadership
  • Facts & Figures
  • Community Health Improvement
  • For Media
  • Miller School of Medicine
  • University of Miami
  • Careers
  • Volunteers
  • Supply Chain
  • Contact Us

Medical Disclaimer | Terms of Use | Privacy Statement | HIPAA Notice of Privacy Practices | Non-Discrimination Policy | No Surprises Billing Rights
© 2026 University of Miami Health System. All rights reserved.